Conor F. Larkin

Ligand Pharmaceuticals on its royalty financing with Castle Creek Biosciences, to support the Phase 3 study of D-Fi, Castle Creek’s lead candidate, in patients with dystrophic epidermolysis bullosa.*

Ligand Pharmaceuticals on its purchase of third-party and synthetic royalty interests from Agenus Inc. to support Agenus’s ongoing botensilimab and balstilimab clinical development program.*

Integra LifeSciences Holdings on its acquisition of Acclarent Inc., a medical device company supporting ENT surgeons with minimally invasive technologies, from Johnson & Johnson.*

Integra LifeSciences Holdings Corporation on the sale of its Extremity Orthopedics business to Smith+Nephew.*

Healthcare Royalty Partners on numerous royalty monetization transactions, including Genfit SA, Acorda Therapeutics Inc., Albireo Pharma Inc., REGENXBIO Inc., and Rhythm Pharmaceuticals Inc.* 

Antares Pharma on its US$960m sale to Halozyme.*

Nevakar Inc. in royalty monetization transactions with NovaQuest Capital Management and H.I.G. Capital.*

Phathom Pharmaceuticals Inc. on a revenue interest financing for up to US$260m in non-dilutive capital with Sagard Healthcare Partners, NovaQuest Capital Management, and Hercules Capital Inc.*

Medical device tubing manufacturer Fluortek on its sale to Nordson Corporation.*

Aptevo Therapeutics in two royalty monetization transactions.*

HollyFrontier Corp. on its US$1.25bn IDR elimination transaction with Holly Energy Partners, including the acquisition of common units of Holly Energy Partners.*

MPLX LP on the strategic combination of the Whistler Pipeline with Enbridge Inc.’s Rio Bravo Pipeline project, which valued the existing Whistler Pipeline and its subsidiaries at US$4.9bn.*

Fomento Económico Mexicano, S.A.B. de C.V. (FEMSA) on its US$350m acquisition of 250 retail gas stations and convenience stores across New Mexico, Texas, and Arkansas from Delek.*

Buckeye Partners on its sale of South Texas Gateway Terminal, which was jointly owned with affiliates of Marathon Petroleum and Phillips 66 to Gibson Energy Inc. for US$1.1bn.*

HF Sinclair Corporation (f/k/a HollyFrontier Corporation) on its US$1.8bn acquisition on Sinclair Oil.*

Buckeye Partners on its acquisition of Magellan’s independent terminals network comprised of 26 refined petroleum products terminals for US$435m.*

HollyFrontier on its US$350m acquisition of the Puget Sound refinery from Shell.*

HollyFrontier Corp. on the US$655m acquisition of Sonneborn U.S. Holdings Inc. and Sonneborn Coöperatief U.A., one of the world’s largest dedicated suppliers of white oils, petrolatums and waxes.*

A subsidiary of MPLX LP and Marathon Petroleum Corp., on a joint venture with WhiteWater Midstream LLC to acquire a 30% interest in a 323-mile NGL pipeline in Texas from EPIC Midstream LLC.*

HollyFrontier Corp. on its US$845m acquisition of Suncor Energy’s Petro-Canada lubricants business.*